 Quinazolines
"Quinazolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011799
|
| MeSH Number(s) |
D03.438.786
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinazolines".
Below are MeSH descriptors whose meaning is more specific than "Quinazolines".
This graph shows the total number of publications written about "Quinazolines" by people in UAMS Profiles by year, and whether "Quinazolines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2021 | 0 | 1 | 1 | | 2020 | 3 | 1 | 4 | | 2019 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2015 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2013 | 2 | 2 | 4 | | 2011 | 0 | 1 | 1 | | 2010 | 1 | 1 | 2 | | 2009 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2007 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2005 | 2 | 0 | 2 | | 2004 | 0 | 1 | 1 | | 2003 | 4 | 1 | 5 | | 2002 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Quinazolines" by people in Profiles over the past ten years.
-
Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proc Natl Acad Sci U S A. 2021 04 13; 118(15).
-
Kachur E, Roshdy D, Hamadeh I, Dodd B, Shahid Z. Single-center experience with use of letermovir for treatment of CMV infection in stem cell transplant recipients. Transpl Infect Dis. 2021 Apr; 23(2):e13502.
-
Lakkaniga NR, Zhang L, Belachew B, Gunaganti N, Frett B, Li HY. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression. Eur J Med Chem. 2020 Oct 01; 203:112589.
-
Johnsrud JJ, Nguyen IT, Domingo W, Narasimhan B, Efron B, Brown JW. Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 2020 10; 26(10):1963-1970.
-
Fang B, Kannan A, Zhao S, Nguyen QH, Ejadi S, Yamamoto M, Camilo Barreto J, Zhao H, Gao L. Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts. Sci Rep. 2020 06 01; 10(1):8867.
-
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, Matulonis UA. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 04 01; 30(4):551-557.
-
Kaur G, Cholia RP, Joshi G, Amrutkar SM, Kalra S, Mantha AK, Banerjee UC, Kumar R. Anticancer activity of dihydropyrazolo[1,5-c]quinazolines against rat C6 glioma cells via inhibition of topoisomerase II. Arch Pharm (Weinheim). 2018 Jun; 351(6):e1800023.
-
Klair JS, Abraham RR, Jones J, Girotra M. A 'shock-ing' endoscopic finding on esophagogastroduodenoscopy. BMJ Case Rep. 2015 Feb 09; 2015.
-
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct; 15(11):1207-14.
-
Petty WJ, Laudadio J, Brautnick L, Lovato J, Dotson T, Streer NP, Weaver KE, Miller AA. Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer. Int J Oncol. 2013 Dec; 43(6):2057-63.
-
Hannesdóttir L, Tymoszuk P, Parajuli N, Wasmer MH, Philipp S, Daschil N, Datta S, Koller JB, Tripp CH, Stoitzner P, Müller-Holzner E, Wiegers GJ, Sexl V, Villunger A, Doppler W. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol. 2013 Oct; 43(10):2718-29.
-
Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|